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This paper describes the design and synthesis of a potential antimalarial compound, 
chloroquinoline-cassiarin (6) using 4,7-dichloroquinoline and the natural product barakol (1) 
extracted from the leaves of Cassia siamea as starting materials. In this paper a one compound-
two-pharmacophores concept is introduced in which coupling of two known pharmacophores into 
one has been described. The concept is not only useful to organic synthesis but also to drug 
development researches. The synthesized compound 6 exhibited potent in vitro antimalarial 
activity at IC50 = 0.51 µM, and low toxicity where at 20 µM, 80% viability of HeLa cells was 
observed. 
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INTRODUCTION 
Malaria, a curable and preventable disease, 
is still a life-threatening disease in Tanzania 
as well as in other endemic sub-Saharan 
African countries. However, according to 
WHO report, malaria cases have dropped 
globally from 262 million in 2000 to 214 
million in 2015 which was 18% drop (WHO 
2016). 
 
Despite the efforts of eradicating malaria by 
using various therapies such as quinine, 
chloroquine, amodiaquine and many other 
known antiplasmodial compounds, the 
disease is still a number one killer in many 
African countries. The development of drug 
resistant strains of Plasmodium species has 
been known to thwart these (Ursos and 
Roepe 2002, Teixeira et al. 2011). 
Therefore, this calls for the development of 
compounds with not only antiplasmodial 
activity but also with needed 
pharmacokinetic activity. The plant Cassia 
siamea (Mjohoro or Mbaraka in Swahili, 
Tanzania) is known to be used for the 
treatment of periodic fever and malaria 
(Phaiphan et al. 2014, chanting et al. 2009, 
Oshimi et al. 2009, Kamagaté et al. 2014, 
Monton et al. 2015). Barakol (1) was the 
first natural product compound to be isolated 
from C. siamea (Hassanalli et al. 1969). Two 
other potent antimalarial alkaloids, 
cassiarins A and B have been isolated from 
this plant, thus in a way authenticating its 
folk medicinal use. The chemical structure 
of barakol (1) is similar to that of cassiarins 
in that the oxygen at position 4 is replaced 
by the nitrogen atom in the cassiarins. 
Unlike the cassiarins, barakol does not 
exhibit antimalarial activity. It is noteworthy 
that a number of cassiarins have been 
derived from barakol by replacing the O 
with N at the position 4 (Kanputhorn et al. 
2010).  
 
The cassiarins A and B are known to be less 
abundant (0.0008% and 0.0017% 
respectively) in their natural source than 
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compound 1 (0.3%) (Kanputhorn et al. 2010, 
Morita et al. 2007). Since an improved 
procedure for obtaining large quantities of 
compound 1 from C. siamea leaves has been 
established (Monton et al. 2015, Hassanalli 
et al. 1969, kanputhorn et al. 2010), 
availability and procurement of this material 
from its sources is cheap and guaranteed. 
Thus, it was envisioned that coupling of an 
amino-derivative of 4,7-dichloroquinoline (5 
with barakol (1) will result in a compound 
with higher antimalarial activities. The 
resulting coupled compound was 
hypothesized to have enhanced antimalarial 
activity and less prone to drug resistance, 
borrowing the ideas from the concept of 
combination therapy (WHO 2010, Nosten et 
al. 2000, Rosenthal 2003). In this approach, 
instead of combining two separate drugs, 
their biologically active parts are contained 
in one compound, a concept known as one-
compound-two-pharmacophore. 
Consequently, the study reported in this 
paper aims at utilizing barakol (1) which is a 
locally available natural product, to 
synthesize a new antimalarial compound (6) 
and evaluate its antimalarial activity. 
 
EXPERIMENT 
Plant Leaves and Material Collections 
The leaves of Cassia siamea (Lam.) Irwin & 
Barneby (Fig. 1) were hand-picked from 
University of Dar es Salaam (UDSM) where 
the plants are grown for ornamental 
purposes. Identification and authentication 
was done at the herbarium in the Department 
of Botany, University of Dar es Salaam 




Figure 1: Cassia siamea at the UDSM 
campus (Photographed by T.M. Kalenga 
2016) 
 
Instruments and Materials (Chemicals 
and Reagents) 
IR data recording was done using Alpha 
ATR FT-IR Spectrometer Bruker Optic 
GmH 2011, and Bruker A.G spectrometer 
(at either 300 MHz or 60 MHz NMR) was 
used for 
1
H NMR and 
13
C NMR spectra 
recording in deuterated methanol (MeOD) or 
DMSO. IR spectra for each compound were 
collected between 4000 and 500 cm
-1
 in 
appropriate resolution. Solvent removal 
from the products was done by using 
BUCHI Rotar Vapor R-205, vacuum 
controller V-800 heating bath B-490 and 
vacuum aspirator B-169. 
 
Extraction and Isolation of Barakol (1) 
A portion of the hand-picked leaves of 
Cassia siamea were sliced while fresh (600 
g) and boiled for 45 minutes in 1.0L of 0.5% 
sulfuric acid, the procedure was repeated 
twice. Sodium carbonate (Na2CO3) was used 
to neutralize the extract, followed by 
extraction with DCM, then solvent 
evaporation to a quarter of the starting 
volume on a rotary evaporator under reduced 
pressure. A proportional amount of cold 
water (approx. 0˚C) was added, shaken and 
left to cool in a refrigerator for 1 hour; 
yellow needle-like solids of barakol (1) were 
filtered, washed with small amount of cold 
water, and dried in an air oven to obtain 1.8 
g (0.3%). 
 




The remaining portion of the leaves was air-
dried, ground to powder (600 g) and the 
same procedure was repeated to afford 0.84 
g (0.14%) of barakol (1): Mp 172-173 ºC 
(decomposition); the IR vmax cm
-1
 3233.16 
(OH), 1676.55 (C-C=C-O-C), 1561.01 and 
1453.84 (aromatic ring). 
1
H NMR (300 
MHz, MeOH): δH 0.72 (s, 3H), 0.89 (s, 3H), 
1.73 (1H), 4.71 (1H), 4.86 (1H) and 4.95 
(1H). 
13
C NMR (300 MHz, MeOH): δC 
19.07, 20.66, 100.47, 105.69, 105.95, 
108.83, 113.86, 133.94, 156.69, 160.44, 
163.88, 170.89 and 184. 20. 
Synthesis of Anhydrobarakol Chloride (3) 
To a solution of 1 (0.500 g, 2.15 mmol) in 
methanol (4.0 mL), concentrated 
hydrochloric acid (1.0 mL) were slowly 
added at room temperature while stirring, 
the mixture was left stirring for 30 mins. 
Yellow solids were formed, the mixture was 
then cooled in ice cold water where 10 mL 
of THF were added for precipitation, 
followed by filtering, washing with THF to 
afford yellow solids of 3 [0.42 g (78%)]. Mp 
203-204 ºC (decomposition); IR vmax cm
-1
 
3438.99 to 3495.72 (OH), 2852.11 to 
3028.59 (sp
2
 C-H), 2541.47 to 2752.56 (sp
3
 
C-H), 1659.92 (C-C=C-O-C), 1561.93 and 





Ethane diamine (5.0 mL, 74.88 mmol) was 
added to dichloroquinoline (7) (5.0 g, 22.25 
mmol) and refluxed for six hours at 92 ˚C, 
while the reaction mixture is monitored by 
TLC. Upon completion, the mixture was 
cooled, 1M NaOH (10 mL) was added and 
then extracted with dichloromethane (300 × 
3 mL). The organic layers were washed with 
brine, dried over anhydrous magnesium 
sulfate, filtered and then evaporated under 
reduced pressure to obtain 2.1 g of 
compound 5 as pale yellow solids in the 
yield 41.8%. Mp 126 ºC, the IR vmax cm
-1
 
3354.62 (N-H), 3243.49 (-NH2), 2893.12 (C-
H) and 1577.39 C=C (aromatic ring).
 1
H 
NMR (300 MHz, MeOD): δH 2.96 (m, 2H), 
3.41 (m, 2H); δH 6.52 (d, 1H), 7.36 (d, 1H), 
7.75 (s, 1H), 8.07 (d, 1H) and 8.33 (d, 
1H).
13
C NMR (300 MHz, MeOD): δC 40.87, 
46.36, 99.68, 118.78, 124.27, 125.98, 
127.60, 136.29, 149.65, 152.42 and 152.77. 
 
Synthesis of Chloroquinoline Cassiarin  
To a 0.44 g (1.755 mmol) of anhydrobarakol 
chloride (3) in 4.0 mL methanol, 0.48 g 
(2.165 mmol) of N-(2-aminoethyl)-7-
chloroquinolin-4-amine (5) were added at 
room temperature, the mixture was stirred 
for 1 hour. 2.0 mL of pyridine were then 
added and stirring continued for 70 minutes 
where 1.0 mL of concentrated HCl were 
added, the mixture was then left stirring for 
14 hours. Through TLC the reaction was 
monitored, upon completion, methanol was 
evaporated followed by addition of THF for 
precipitation. Addition of 6.0 mL of distilled 
water, cooling in ice cold water and addition 
of Na2CO3 solution to pH 7.8 gave yellow 
solids. Filtering, washing and drying of the 
solids afforded 0.38 g (52%) of compound 6. 
Mp 276-278 ºC (decomposition); IR vmax 
cm
-1
 3204.44 (N-H), 1640.39 (C=O, 
conjugated), 1580. (C=C, aromatic) and 
1139.83 (C-O). 
1
H NMR (300 MHz, MeOH) 
δH 1.38 (s, 3H) and 2.38 (s, 3H), 3.36 (m, 
2H), 3.34 (m, 2H), 6.77 (1H), 6.88 (m, 1H), 
6.91 (m, 1H), 7.19 (1H), 7.52 (m, 1H), 7.82 
(1H), 8.26 (m, H), 8.32 (m, 1H) and 8.44 (m, 
1H). 
 
Brine Shrimp Assay 
Sterile artificial sea water in which brine 
shrimp (Artemia salina) eggs were hatched 
was prepared by dissolving 3.8 g of artificial 
sea salt in 1.0 L distilled water to make 
3.8g/L. Solutions of compounds 1 and 6 in 
varying concentrations (240, 120, 80, 40 and 
24 µg/mL) were prepared separately in 
DMSO. The solutions were added into a vial 
and in each 10 active nauplii were added 
then the volume adjusted to 5 mL with 
artificial sea water. The test experiment was 
performed in duplicates for each 
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concentration. The vials containing larvae 
were incubated under light for 24 hrs and the 
numbers of dead larvae were counted, 
percentage was calculated as: (Test – 
Control)/(control) times 100. The 
cytotoxicity of barakol (1) and compound 6 
was determined from LC50 value per dose. 
Cyclophosphamide was used control 
experiment (Bycroft et al. 1970, 




HeLa cell line Assay 
Culturing of HeLa cells was done in 5% CO2 
at 37 
o
C incubator in Dulbecco’s modified 
eagle medium (DMEM) with 4.5 g/L 
glucose and 4 mM L-glutamine. Treatment 
with 10% foetal calf serum and antibiotics; 
such as streptomycin (0.1 mg/mL), penicillin 
(100 mg/mL) and amphotericin (0.25 
µg/mL). These cells were cultured in 96 well 
microplates at 10
4
 cells per well and left 
overnight. Compound 6 (20 µM) was 
incubated with the cells for additional 24 
hrs, and emetine standard was used as a 
positive control. Cell viability in the wells 
was assessed by adding 20 µL solution of 
mixture of MTT and PBS (phosphate-buffer 
solution) in the culture medium for each 
well and incubated for additional four hours 
at constant conditions. Fluorescence 
readings (excitation 560 nm, emission 590 
nm) obtained for the individual wells were 
converted to percentage (%) cell viability 
relative to the average readings obtained 
from untreated control wells (Natarajan et al 
2008).  
 
Antimalarial Assay  
Chloroquine sensitive strain (3D7) of 
parasite (Plasmodium falciparum) were 
cultured in 25mM medium of hepes and 2 
mM L-glutamine, and supplemented with 2-
4% (v/v) human erythrocytes, 0.5% (w/v) 
Albumax II (Thermo Fisher Scientific), 
0.05mg/mL and 0.65 mM. Common 
standard culturing medium RPM1 1640 
under 5% CO2, 5% O2 and 90% N2 
atmosphere cell culture were maintained at 
constant temperature (37 ºC). For evaluation 
of antiplasmodial activity, parasite cultures 
(adjusted to 2% parasitemia, 1% 
haemotocrit) were placed in 96-well plates 
and incubated with 20 µM of compound 6 
for 48 hours. Parasite lactate dehydrogenase 
(pLDH) enzyme was used to evaluate in 
vitro antiplasmodial activity. Nitro blue 
tetrazolium (NBT) is employed in the LDH 
determination, where NBT is reduced to 
formazan and detected at 620 nm. Duplicate 
wells for concentrations of both compound 6 
and chloroquine standard were used. 
Enzyme (pLDH) activity in the individual 
wells was subsequently determined by 
removing 20 µL of the parasite cultures and 
mixing it with 125 µL colorimetric substrate 
solution containing 44 mM Tris buffer (pH 
9), 0.18 M L-lactic acid, 0.13 mM 
acetylpyridine adenine dinucleotide, 0.39 
mM NBT chloride, 0.048 mM phenazine 
ethosulfate and 0.16% (v/v) Triton X-100. 
Colour development was monitored by 
measuring absorbance at 620 nm in a 
Spectramax M3 plate reader (Molecular 
Devices). Absorbance values were converted 
to percentage (%) parasite viability relative 
to untreated control cultures. The mean IC50 
inhibition at each concentration of 
compound 6 and standard were concurrently 
determined, and the parasite viability 
percentage value was calculated in the probit 
(Natarajan et al. 2008).  
 
RESULTS AND DISCUSSION 
Extraction and Purification of Barakol 
Barakol (1) which is the starting material 
was successfully extracted from the leaves 
of C. siamea using the published procedure 
(Kanputhorn et al. 2010) and (Monton et al. 
2015) which was adopted with slight 
modification. The obtained barakol (1) was 





The obtained data were consistent with those 
reported in the literature (Monton et al. 
2015, Pavia et al. 2001). 






As illustrated in Scheme 1, the conversion 
of compound 1 to cassiarins can be achieved 
either by direct amination of compound 1 
using ammonium salts (Scheme 1i) or by 
amination of the chloride salt (3) of 1 
(Scheme 1ii). The approach of Scheme 1(ii) 
is general and allows a one-step introduction 
of many amines unlike Scheme 1(i) where 
only ammonia/its salts are used. The latter 
approach, with slight modification, was 
employed in the synthesis of the target 




Scheme 1: Conversion of barakol 1 to Cassiarins 
 
The first step towards the synthesis of the 
target molecule (6) involved the 
transformation of barakol (1) into precursor 
3 using literature procedure (Kanputhorn et 
al 2010) and (Bycroft et al. (1970). Then, 
the obtained anhydrobarakol (3) was treated 
with compound 5 (N-(2-aminoethyl)-7-
chloroquinolin-4-amine) in the presence of 
the pyridine in methanol to afford pale 
yellow crystals of the desired compound 6 as 
shown in Scheme 2.  
 
Scheme 2: Conversion of 1 to 6 
However, the preparation of compound 5 
which is one of the starting material 
precursor of this molecule was achieved by 
amination of dichloroquinoline (7) following 
the procedure described in the literature 





C NMR, confirmed the 
structural configuration of this compound. 
 
 




Scheme 3: Synthesis of Precursor 5 from 4,7-Dichloroquinoline (7) 
 
The structural characterization of the target 
molecule 6 was established using FT-IR and 
1
H NMR. The 
1
H NMR spectrum of 
compound 6 had two methyl proton signals 
characteristic of a tricyclic ring indicated by 
singlet signals at δH 1.38 (s, 3H) and 2.38 (s, 
3H).
 
Ethylene protons were observed as 
multiplets at δH 3.36 (m, 2H) and 3.34 (m, 
2H). On the other hand, the methylene 
protons of the tricyclic ring and 
chloroquinoline were observed as nine 
multiplet signals at δH 6.77 (1H), 6.88 (m, 
1H), 6.91 (m, 1H), 7.19 (1H), 7.52 (m, 1H), 
7.82 (1H), 8.26 (m, H), 8.32 (m, 1H) and 
8.44 (m, 1H). [20-22]. The stated 
spectroscopic data are consistent with the 
structure of the synthesized compound 4-(2-
(7-chloroquinolin-4-ylamino)ethyl-2,5-
dimethylpyranol[2,3,4-ij]isoquinoline-
8(4H)-one (6). Like compound 1, compound 
6 in methanol was observed to be very 
sensitive to light, since within 48 hours of 
exposure it changed from pale green to dark 
green. For stability, solutions of both 




Upon Brine Shrimp testing, compound 1 
showed cytotoxic activity at LC50 = 3097 
µg/mL while that of target compound 6 was 
found to be 333 µg/mL. The cytotoxicity of 
compound 6 seems to be influenced by the 
coupled moieties, this is because, compound 
1 showed very low cytotoxic activity. 
 
To confirm further the cytotoxic activity of 
compounds 1 and 6, HeLa cell lines were 
used with emetine as a standard. At 20 µM 
of compound 6, 80% viability of HeLa cells 
was observed, indicating the compound to 
be less toxic. The viability percentage of 
emetine standard was only high at low 
concentrations (0.012346-0.000457 µM). 
 
The parasite (Plasmodium falciparum) 
lactate dehydrogenase (pLDH) enzyme was 
used as an indicator of in vitro 
antiplasmodial activity of the compounds. 
The assessment was done following the 
procedure described by Naghibi et al. (2013) 
(Naghibi et al. 2013) against the chloroquine 
sensitive (3D7) strain of parasite.
 
The in 
vitro antimalarial evaluation of compound 6 
was found to be IC50 = 0.51 µM while that 
of chloroquine (standard) was IC50 = 0.0011 
µM. Compound 6 (an analogue of cassiarin 
B) exhibited higher activity than that of 
cassiarin B (IC50 = 21.9 µM). Therefore, 
coupling of the quinoline pharmacophore 
with that of cassiarin B has enhanced the 
activity of the compound.  
 
CONCLUSION 
To conclude, the design, synthesis and 
antimalarial assay of a new compound with 
two antimalarial pharmacophores has been 
achieved. Barakol (1) from the leaves of C. 
siamea was coupled to chloroquinoline 
derivative 5 to form compound 6.  In vitro 
antimalarial activity of the synthesized 
compound 6 is reported here together with 
its cytotoxicity results. Indeed the 
synthesized compound was found to be more 
potent than the corresponding cassiarin B. 
 
Based on the good results from this 
preliminary study, work is underway to 
assess the effect of the length of the carbon 
chain linking the two pharmacophores and 




as well as the effects of placing the linker at 
C-8 instead of the C-4 position. Since 
cassiarin A with an unsubstituted N is more 
potent than cassiarin B and since 
chloroquinoline-barakol analogue of 
cassiarin B is more potent therefore, it is 
expected that chloroquinoline-barakol 
analogue of cassiarin A may similarly be 
more potent.  
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